Literature DB >> 26826202

Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.

Ralf S Schmid1, Jeremy M Simon1, Mark Vitucci1, Robert S McNeill1, Ryan E Bash1, Andrea M Werneke1, Lauren Huey1, Kristen K White1, Matthew G Ewend1, Jing Wu1, C Ryan Miller1.   

Abstract

BACKGROUND: Glioma stem cells (GSCs) from human glioblastomas (GBMs) are resistant to radiation and chemotherapy and may drive recurrence. Treatment efficacy may depend on GSCs, expression of DNA repair enzymes such as methylguanine methyltransferase (MGMT), or transcriptome subtype.
METHODS: To model genetic alterations in human GBM core signaling pathways, we induced Rb knockout, Kras activation, and Pten deletion mutations in cortical murine astrocytes. Neurosphere culture, differentiation, and orthotopic transplantation assays were used to assess whether these mutations induced de-differentiation into GSCs. Genome-wide chromatin landscape alterations and expression profiles were examined by formaldehyde-assisted isolation of regulatory elements (FAIRE) seq and RNA-seq. Radiation and temozolomide efficacy were examined in vitro and in an allograft model in vivo. Effects of radiation on transcriptome subtype were examined by microarray expression profiling.
RESULTS: Cultured triple mutant astrocytes gained unlimited self-renewal and multilineage differentiation capacity. These cells harbored significantly altered chromatin landscapes that were associated with downregulation of astrocyte- and upregulation of stem cell-associated genes, particularly the Hoxa locus of embryonic transcription factors. Triple-mutant astrocytes formed serially transplantable glioblastoma allografts that were sensitive to radiation but expressed MGMT and were resistant to temozolomide. Radiation induced a shift in transcriptome subtype of GBM allografts from proneural to mesenchymal.
CONCLUSION: A defined set of core signaling pathway mutations induces de-differentiation of cortical murine astrocytes into GSCs with altered chromatin landscapes and transcriptomes. This non-germline genetically engineered mouse model mimics human proneural GBM on histopathological, molecular, and treatment response levels. It may be useful for dissecting the mechanisms of treatment resistance and developing more effective therapies.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Astrocytes; glioblastoma; glioma stem cells; radiation; temozolomide

Mesh:

Substances:

Year:  2016        PMID: 26826202      PMCID: PMC4896545          DOI: 10.1093/neuonc/nov321

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  61 in total

Review 1.  From stem cells to neurons and glia: a Soxist's view of neural development.

Authors:  Michael Wegner; C Claus Stolt
Journal:  Trends Neurosci       Date:  2005-08-31       Impact factor: 13.837

2.  Genome-wide atlas of gene expression in the adult mouse brain.

Authors:  Ed S Lein; Michael J Hawrylycz; Nancy Ao; Mikael Ayres; Amy Bensinger; Amy Bernard; Andrew F Boe; Mark S Boguski; Kevin S Brockway; Emi J Byrnes; Lin Chen; Li Chen; Tsuey-Ming Chen; Mei Chi Chin; Jimmy Chong; Brian E Crook; Aneta Czaplinska; Chinh N Dang; Suvro Datta; Nick R Dee; Aimee L Desaki; Tsega Desta; Ellen Diep; Tim A Dolbeare; Matthew J Donelan; Hong-Wei Dong; Jennifer G Dougherty; Ben J Duncan; Amanda J Ebbert; Gregor Eichele; Lili K Estin; Casey Faber; Benjamin A Facer; Rick Fields; Shanna R Fischer; Tim P Fliss; Cliff Frensley; Sabrina N Gates; Katie J Glattfelder; Kevin R Halverson; Matthew R Hart; John G Hohmann; Maureen P Howell; Darren P Jeung; Rebecca A Johnson; Patrick T Karr; Reena Kawal; Jolene M Kidney; Rachel H Knapik; Chihchau L Kuan; James H Lake; Annabel R Laramee; Kirk D Larsen; Christopher Lau; Tracy A Lemon; Agnes J Liang; Ying Liu; Lon T Luong; Jesse Michaels; Judith J Morgan; Rebecca J Morgan; Marty T Mortrud; Nerick F Mosqueda; Lydia L Ng; Randy Ng; Geralyn J Orta; Caroline C Overly; Tu H Pak; Sheana E Parry; Sayan D Pathak; Owen C Pearson; Ralph B Puchalski; Zackery L Riley; Hannah R Rockett; Stephen A Rowland; Joshua J Royall; Marcos J Ruiz; Nadia R Sarno; Katherine Schaffnit; Nadiya V Shapovalova; Taz Sivisay; Clifford R Slaughterbeck; Simon C Smith; Kimberly A Smith; Bryan I Smith; Andy J Sodt; Nick N Stewart; Kenda-Ruth Stumpf; Susan M Sunkin; Madhavi Sutram; Angelene Tam; Carey D Teemer; Christina Thaller; Carol L Thompson; Lee R Varnam; Axel Visel; Ray M Whitlock; Paul E Wohnoutka; Crissa K Wolkey; Victoria Y Wong; Matthew Wood; Murat B Yaylaoglu; Rob C Young; Brian L Youngstrom; Xu Feng Yuan; Bin Zhang; Theresa A Zwingman; Allan R Jones
Journal:  Nature       Date:  2006-12-06       Impact factor: 49.962

3.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.

Authors:  Robert S McNeill; Ralf S Schmid; Ryan E Bash; Mark Vitucci; Kristen K White; Andrea M Werneke; Brian H Constance; Byron Huff; C Ryan Miller
Journal:  J Vis Exp       Date:  2014-08-12       Impact factor: 1.355

Review 4.  Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Authors:  S S Agarwala; J M Kirkwood
Journal:  Oncologist       Date:  2000

5.  Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

Authors:  Lionel M L Chow; Raelene Endersby; Xiaoyan Zhu; Sherri Rankin; Chunxu Qu; Junyuan Zhang; Alberto Broniscer; David W Ellison; Suzanne J Baker
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

6.  U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line.

Authors:  Michael James Clark; Nils Homer; Brian D O'Connor; Zugen Chen; Ascia Eskin; Hane Lee; Barry Merriman; Stanley F Nelson
Journal:  PLoS Genet       Date:  2010-01-29       Impact factor: 5.917

7.  Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.

Authors:  Mark Vitucci; Natalie O Karpinich; Ryan E Bash; Andrea M Werneke; Ralf S Schmid; Kristen K White; Robert S McNeill; Byron Huff; Sophie Wang; Terry Van Dyke; C Ryan Miller
Journal:  Neuro Oncol       Date:  2013-06-27       Impact factor: 12.300

Review 8.  Emerging role of nanog in tumorigenesis and cancer stem cells.

Authors:  Luis E Iv Santaliz-Ruiz; Xiujie Xie; Matthew Old; Theodoros N Teknos; Quintin Pan
Journal:  Int J Cancer       Date:  2014-01-13       Impact factor: 7.396

9.  In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.

Authors:  Stephanie E Combs; Daniela Schulz-Ertner; Wilfried Roth; Christel Herold-Mende; Jürgen Debus; Klaus-Josef Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-07-01       Impact factor: 7.038

Review 10.  Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.

Authors:  Dagmar Beier; Joerg B Schulz; Christoph P Beier
Journal:  Mol Cancer       Date:  2011-10-11       Impact factor: 27.401

View more
  18 in total

1.  KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway.

Authors:  Yang Gao; Liangdong Li; Hui Zheng; Changshuai Zhou; Xin Chen; Bin Hao; Yiqun Cao
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

2.  Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.

Authors:  C J Herting; Z Chen; K L Pitter; F Szulzewsky; I Kaffes; M Kaluzova; J C Park; P J Cimino; C Brennan; B Wang; D Hambardzumyan
Journal:  Glia       Date:  2017-08-24       Impact factor: 7.452

3.  MerTK as a therapeutic target in glioblastoma.

Authors:  Jing Wu; Lauren N Frady; Ryan E Bash; Stephanie M Cohen; Allison N Schorzman; Yu-Ting Su; David M Irvin; William C Zamboni; Xiaodong Wang; Stephen V Frye; Matthew G Ewend; Erik P Sulman; Mark R Gilbert; H Shelton Earp; C Ryan Miller
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

4.  Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.

Authors:  Onyinyechukwu Okolie; Juli R Bago; Ralf S Schmid; David M Irvin; Ryan E Bash; C Ryan Miller; Shawn D Hingtgen
Journal:  Neuro Oncol       Date:  2016-06-13       Impact factor: 12.300

5.  Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models.

Authors:  David M Irvin; Robert S McNeill; Ryan E Bash; C Ryan Miller
Journal:  Brain Pathol       Date:  2016-04-13       Impact factor: 6.508

6.  Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.

Authors:  Mark Vitucci; David M Irvin; Robert S McNeill; Ralf S Schmid; Jeremy M Simon; Harshil D Dhruv; Marni B Siegel; Andrea M Werneke; Ryan E Bash; Seungchan Kim; Michael E Berens; C Ryan Miller
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

7.  Inhibition of Colony-Stimulating Factor-1 Receptor Enhances the Efficacy of Radiotherapy and Reduces Immune Suppression in Glioblastoma.

Authors:  Muayad F Almahariq; Thomas J Quinn; Pravin Kesarwani; Shiva Kant; C Ryan Miller; Prakash Chinnaiyan
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

8.  Neuronal activity modifies the chromatin accessibility landscape in the adult brain.

Authors:  Yijing Su; Jaehoon Shin; Chun Zhong; Sabrina Wang; Prith Roychowdhury; Jongseuk Lim; David Kim; Guo-Li Ming; Hongjun Song
Journal:  Nat Neurosci       Date:  2017-02-06       Impact factor: 24.884

9.  Revisit the Candidacy of Brain Cell Types as the Cell(s) of Origin for Human High-Grade Glioma.

Authors:  Fangjie Shao; Chong Liu
Journal:  Front Mol Neurosci       Date:  2018-02-21       Impact factor: 5.639

10.  Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

Authors:  Robert S McNeill; Demitra A Canoutas; Timothy J Stuhlmiller; Harshil D Dhruv; David M Irvin; Ryan E Bash; Steven P Angus; Laura E Herring; Jeremy M Simon; Kasey R Skinner; Juanita C Limas; Xin Chen; Ralf S Schmid; Marni B Siegel; Amanda E D Van Swearingen; Michael J Hadler; Erik P Sulman; Jann N Sarkaria; Carey K Anders; Lee M Graves; Michael E Berens; Gary L Johnson; C Ryan Miller
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.